Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Study Summary

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.

Conditions

Carcinoid Syndrome Carcinoid Carcinoid Tumor Carcinoid Tumor of Ileum Carcinoid Tumor of Cecum Carcinoid Tumor of Liver Carcinoid Tumor of Pancreas Carcinoid Syndrome Diarrhea Carcinoid Intestine Tumor

Interventions / Drugs

Paltusotine Placebo

View on ClinicalTrials.gov ↗

Sponsor

CRNX

Crinetics Pharmaceuticals

Endocrinology

D39/100

Study Details

Enrollment141 participants

Primary Completion—

Lead SponsorCrinetics Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:10:51.260399+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.